Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results

Celldex Therapeutics (NASDAQ:CLDX) posted its quarterly earnings data on Monday. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.13), Zacks reports. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%.

Celldex Therapeutics Price Performance

Shares of NASDAQ CLDX opened at $24.37 on Wednesday. The stock has a market capitalization of $1.62 billion, a PE ratio of -8.10 and a beta of 1.36. Celldex Therapeutics has a one year low of $14.40 and a one year high of $29.05. The business’s fifty day moving average price is $25.48 and its 200-day moving average price is $22.80.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on CLDX. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Celldex Therapeutics in a report on Wednesday, October 8th. Citigroup cut their price objective on Celldex Therapeutics from $56.00 to $48.00 and set a “buy” rating on the stock in a research report on Wednesday, August 20th. Barclays decreased their target price on Celldex Therapeutics from $25.00 to $21.00 and set an “underweight” rating for the company in a research report on Tuesday. Mizuho started coverage on shares of Celldex Therapeutics in a report on Tuesday, October 21st. They issued an “outperform” rating and a $48.00 price target on the stock. Finally, Canaccord Genuity Group restated a “buy” rating and set a $62.00 price objective on shares of Celldex Therapeutics in a report on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $43.80.

Institutional Investors Weigh In On Celldex Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Russell Investments Group Ltd. lifted its holdings in Celldex Therapeutics by 27.6% during the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 501 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Celldex Therapeutics by 1.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,451 shares of the biopharmaceutical company’s stock valued at $798,000 after purchasing an additional 680 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Celldex Therapeutics by 289.6% during the 2nd quarter. Tower Research Capital LLC TRC now owns 7,247 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 5,387 shares in the last quarter. Headlands Technologies LLC bought a new position in Celldex Therapeutics in the 2nd quarter worth approximately $125,000. Finally, Jump Financial LLC boosted its holdings in Celldex Therapeutics by 53.3% in the 2nd quarter. Jump Financial LLC now owns 29,503 shares of the biopharmaceutical company’s stock worth $600,000 after buying an additional 10,255 shares during the period.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.